By Dr. Mercola
In recent years, research has suggested trimethylamine-N-oxide (TMAO) might be a therapeutic target for insulin resistance and gastrointestinal (GI) cancers. As noted in one 2017 scientific review:1
“Through the digestion of animal protein and other constituents of animal products, the commensal bacteria in the gut (the gut microbiota) forms metabolites that can contribute to the development of both insulin resistance and cancer.
Trimethylamine-N-oxide (TMAO) is such a molecule and has recently drawn a lot of attention as it may be a risk factor for — and a link …read more
Source: mercola
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr